Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises H Intressenter in connection with offer for Höganäs
Mandate

Vinge advises H Intressenter in connection with offer for Höganäs

February 14, 2013

FAM (Foundation Asset Management Sweden AB) and Lindéngruppen AB have, through the jointly owned company H Intressenter AB, announced a public offer for all of the shares in Höganäs AB. The offer values Höganäs AB at approximately SEK 11.2 billion.

Höganäs AB is the world’s leading producer of metal powder. The company’s class B shares are listed on NASDAQ OMX Stockholm.

Vinge and Hannes Snellman are advising H Intressenter AB. Vinge’s team is led by responsible partner Göran Nyström and also consists of Charlotte Levin, Jo-Anna Nordström and Oskar Belani as well as Johan Cederblad (environmental), Mikael Ståhl and Marie Brommesson (financing) as well as Johan Karlsson and Peter Alstergren (competition).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026